Abstract: Compositions and methods are provided that are effective in treating skin hyperproliferative disorders. These include a topical pharmaceutical preparation that includes a compound that has two or more of a SRC-kinase inhibiting activity, a tubulin polymerization inhibiting activity, an activity that arrests the cell cycle at G2/M, and an activity that induces apoptosis. The compound KX01 is provided as an example of such a compound. The topical pharmaceutical preparation further includes a vitamin D derivative or a retinoid, where the combination provides a synergistic effect. Use of the topical pharmaceutical preparation can be combined with exposure to blue, UVA, or UVB light, which provides a synergistic effect.

Abstract: A phototherapy device, a kit containing such a phototherapy device, and a method for treating a patient with a phototherapy device, the phototherapy device containing a housing, an emission portion, and a light tube, the housing containing a light source that emits light at a wavelength of from about 400 nm to about 550 nm, and may contain a light shield proximal to the light source, the emission portion being distal form the housing and connected thereto via a light tube which contains an optical fibre, and a mesh that may enclose the optical fibre and may allow a limited amount of light to leak from the optical fibre to the outside environment.

Abstract: Compositions and methods are provided that are effective in treating skin hyperproliferative disorders. These include a topical pharmaceutical preparation that includes a compound that has two or more of a SRC-kinase inhibiting activity, a tubulin polymerization inhibiting activity, an activity that arrests the cell cycle at G2/M, and an activity that induces apoptosis. The compound KX01 is provided as an example of such a compound. The topical pharmaceutical preparation further includes a vitamin D derivative or a retinoid, where the combination provides a synergistic effect. Use of the topical pharmaceutical preparation can be combined with exposure to blue, UVA, or UVB light, which provides a synergistic effect.

Abstract: A phototherapy device, a kit containing such a phototherapy device, and a method for treating a patient with a phototherapy device, the phototherapy device containing a housing, an emission portion, and a light tube, the housing containing a light source that emits light at a wavelength of from about 400 nm to about 550 nm, and may contain a light shield proximal to the light source, the emission portion being distal form the housing and connected thereto via a light tube which contains an optical fibre, and a mesh that may enclose the optical fibre and may allow a limited amount of light to leak from the optical fibre to the outside environment.

Abstract: The present invention provides for a novel method for treating polyglutamine (polyQ) diseases. Also disclosed are related compositions and kits for therapeutic use in the treatment of polyQ diseases.

Abstract: Disclosed are hydrogel composition, method for preparing the same and use thereof. The hydrogel composition comprises a guar gum derivative which is crosslinked, a mint-based component, water, and optionally, an amphiphilic core-shell nanoparticle having a hydrophobic core and a hydrophilic shell, wherein the amount of the mint-based component is in the range of 1-6 wt % and the amount of the water is in the range of 65-95 wt %, based on the total weight of the hydrogel composition. The hydrogel composition is safe and can provide symptomatic relief for patients with symptoms such as severe and intractable pruritus associated with hypertrophic scars. The symptomatic relief effect of the hydrogel composition is reproducible, and is independent of the etiology of the burn trauma, extent of the scarring and duration of the scar formation, while tachyphylaxis is not observed. Also disclosed is a medical device comprising the hydrogel composition.

Abstract: The present invention provides for a novel method for treating polyglutamine (polyQ) diseases. Also disclosed are related compositions and kits for therapeutic use in the treatment of polyQ diseases.

Abstract: The invention provides compounds, compositions and methods for treating myotonic dystrophy. The compounds can selectively bind to CUG repeats in RNA, or to CTG repeats in DNA, and inhibit replication of the nucleic acids.

Abstract: In accordance with the invention, with an eye swab for cleaning eyes of vertebrate animals, for example dog's eyes, is provided. The eye swab consists of a gel-like putty, wherein the gel-like putty is held together from a reversibly bonded, three-dimensional network formed of at least one natural or synthetic polymer, at least one cross-linking agent and glycerol.

Abstract: The invention provides compounds, compositions and methods for treating myotonic dystrophy. The compounds can selectively bind to CUG repeats in RNA, or to CTG repeats in DNA, and inhibit replication of the nucleic acids.

Abstract: The invention provides compounds, compositions and methods for treating myotonic dystrophy. The compounds can selectively bind to CUG repeats in RNA, or to CTG repeats in DNA, and inhibit replication of the nucleic acids.

Abstract: The invention provides compounds, compositions and methods for treating myotonic dystrophy. The compounds can selectively bind to CUG repeats in RNA, or to CTG repeats in DNA, and inhibit replication of the nucleic acids.